Patient characteristics of 1775 patients and subgroups of patients with and without major bleeding during rivaroxaban therapy
| . | All patients . | No major bleeding . | Major bleeding . | P value: no major bleeding vs major bleeding . |
|---|---|---|---|---|
| N (%) | 1775 (100) | 1716 (96.7) | 59 (3.3) | |
| Male, n (%) | 913 (51.4) | 880 (51.3) | 33 (55.9) | .4823 |
| Age (y) median (IQR) | 74 (14) | 73 (14) | 79 (10.5) | .0016 |
| Mean BMI ± SD (kg/m2) | 28.5 ± 5.1 | 28.6 ± 5.1 | 27.6 ± 4.6 | .1449 |
| Coronary artery disease, n (%) | 311 (17.5) | 297 (17.3) | 14 (23.7) | .2021 |
| Prior stroke or systemic embolism, n (%) | 203 (11.4) | 195 (11.4) | 8 (13.6) | .6023 |
| Concomitant antiplatelet therapy or NSAID, n (%) | 298 (16.8) | 293 (17.1) | 5 (8.5) | .0823 |
| Impaired renal function, n (%)* | 192 (10.8) | 179 (10.4) | 13 (22.0) | .0048 |
| Anticoagulation-naive | 1067 (60.1) | 1030 (60.0) | 37 (62.7) | .6784 |
| . | All patients . | No major bleeding . | Major bleeding . | P value: no major bleeding vs major bleeding . |
|---|---|---|---|---|
| N (%) | 1775 (100) | 1716 (96.7) | 59 (3.3) | |
| Male, n (%) | 913 (51.4) | 880 (51.3) | 33 (55.9) | .4823 |
| Age (y) median (IQR) | 74 (14) | 73 (14) | 79 (10.5) | .0016 |
| Mean BMI ± SD (kg/m2) | 28.5 ± 5.1 | 28.6 ± 5.1 | 27.6 ± 4.6 | .1449 |
| Coronary artery disease, n (%) | 311 (17.5) | 297 (17.3) | 14 (23.7) | .2021 |
| Prior stroke or systemic embolism, n (%) | 203 (11.4) | 195 (11.4) | 8 (13.6) | .6023 |
| Concomitant antiplatelet therapy or NSAID, n (%) | 298 (16.8) | 293 (17.1) | 5 (8.5) | .0823 |
| Impaired renal function, n (%)* | 192 (10.8) | 179 (10.4) | 13 (22.0) | .0048 |
| Anticoagulation-naive | 1067 (60.1) | 1030 (60.0) | 37 (62.7) | .6784 |
BMI, body mass index; NSAID, nonsteroidal anti-inflammatory drug; SD, standard deviation.
Impaired renal function was defined as current or history of GFR <50 mL/min.